MCID: HYP014
MIFTS: 52

Hyperuricemia

Categories: Blood diseases, Metabolic diseases

Aliases & Classifications for Hyperuricemia

MalaCards integrated aliases for Hyperuricemia:

Name: Hyperuricemia 12 74 54 43 15 17 71
Blood Urate Raized 12
Uricacidemia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1920
MeSH 43 D033461
NCIt 49 C3961
SNOMED-CT 67 35885006
ICD10 32 E79.0
UMLS 71 C0740394

Summaries for Hyperuricemia

Disease Ontology : 12 An acquired metabolic disease that has material basis in an abnormally high level of uric acid in the blood.

MalaCards based summary : Hyperuricemia, also known as blood urate raized, is related to lesch-nyhan syndrome and glycogen storage disease ia, and has symptoms including seizures, muscle weakness and polydipsia. An important gene associated with Hyperuricemia is UMOD (Uromodulin), and among its related pathways/superpathways are Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds and Folate Metabolism. The drugs Selenium and Rasburicase have been mentioned in the context of this disorder. Affiliated tissues include kidney, heart and liver, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 74 Hyperuricemia is an abnormally high level of uric acid in the blood. In the pH conditions of body fluid,... more...

Related Diseases for Hyperuricemia

Diseases related to Hyperuricemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 473)
# Related Disease Score Top Affiliating Genes
1 lesch-nyhan syndrome 33.7 XDH SLC2A9 SLC22A12 SLC17A1 HPRT1
2 glycogen storage disease ia 33.4 SLC37A4 INS G6PC
3 autosomal dominant tubulointerstitial kidney disease, ren-related 33.3 UMOD REN
4 hyperuricemic nephropathy, familial juvenile, 1 33.2 UMOD SLC2A9 SLC22A12 HPRT1
5 autosomal dominant tubulointerstitial kidney disease 32.9 UMOD REN
6 gout 32.5 XDH UMOD SLC2A9 SLC22A12 SLC17A3 SLC17A1
7 acute kidney failure 31.4 UMOD SLC22A12 REN GPT
8 chronic kidney disease 31.3 UMOD REN INS CRP APOB
9 urolithiasis 31.3 XDH UMOD HPRT1
10 kidney disease 31.2 XDH UMOD REN INS CRP APOB
11 hypercholesterolemia, familial, 1 31.0 INS GPT CRP APOB
12 lipid metabolism disorder 31.0 INS GGT1 CRP APOB ADRB3
13 end stage renal disease 30.9 UMOD REN INS CRP
14 fatty liver disease 30.8 INS GPT GGT1 CRP APOB
15 nephrolithiasis 30.8 XDH UMOD SLC2A9 SLC22A12 INS HPRT1
16 hypouricemia, renal, 1 30.8 SLC2A9 SLC22A12 HPRT1
17 interstitial nephritis 30.7 UMOD REN CRP
18 vascular disease 30.7 XDH REN INS CRP APOB
19 gastroenteritis 30.7 REN CRP ABCG2
20 non-alcoholic fatty liver disease 30.7 INS GPT GGT1 CRP APOB
21 arteries, anomalies of 30.7 REN INS CRP APOB
22 glycogen storage disease 30.6 SLC37A4 SLC17A3 PFKM INS G6PC CRP
23 lipoprotein quantitative trait locus 30.6 REN GPT CRP APOB
24 anuria 30.6 REN GPT CRP
25 deficiency anemia 30.6 XDH INS GGT1 CRP
26 retinal vascular disease 30.5 REN INS CRP
27 arteriosclerosis 30.5 INS GPT CRP APOB
28 pre-eclampsia 30.5 XDH REN INS GPT CRP ADRB3
29 heart disease 30.5 XDH REN INS GPT CRP APOB
30 pyelonephritis 30.5 UMOD GPT CRP
31 uremia 30.5 REN INS CRP
32 cerebrovascular disease 30.4 REN INS CRP APOB
33 fatty liver disease, nonalcoholic 1 30.4 INS GPT GGT1
34 glucose intolerance 30.4 INS GPT CRP APOB ADRB3
35 hypothyroidism 30.4 REN INS GPT CRP APOB
36 abdominal obesity-metabolic syndrome 1 30.4 INS APOB ADRB3
37 chronic pyelonephritis 30.3 UMOD REN CRP
38 peripheral nervous system disease 30.3 REN INS GPT CRP
39 hyperthyroidism 30.3 INS GPT CRP
40 nephrolithiasis, uric acid 30.3 XDH SLC2A9 SLC22A12 HPRT1
41 vesicoureteral reflux 1 30.2 UMOD REN CRP
42 neutropenia 30.2 SLC37A4 GPT G6PC CRP
43 constipation 30.1 INS GPT GGT1 CRP
44 non-alcoholic steatohepatitis 30.0 INS GPT GGT1
45 acute cystitis 29.9 UMOD REN INS GPT CRP
46 diabetes mellitus 29.9 UMOD REN INS GPT GGT1 G6PC
47 body mass index quantitative trait locus 11 29.9 REN INS GPT GGT1 G6PC CRP
48 peripheral vascular disease 29.8 INS CRP APOB
49 sleep apnea 29.8 REN INS GPT CRP APOB
50 hypertension, essential 29.7 XDH UMOD SLC2A9 SLC22A12 REN INS

Graphical network of the top 20 diseases related to Hyperuricemia:



Diseases related to Hyperuricemia

Symptoms & Phenotypes for Hyperuricemia

UMLS symptoms related to Hyperuricemia:


seizures, muscle weakness, polydipsia, fever, dyspnea, edema, cachexia, vertigo, headache, syncope, cyanosis, icterus, signs and symptoms, signs and symptoms, digestive, hot flushes

MGI Mouse Phenotypes related to Hyperuricemia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.15 ABCG2 ADRB3 G6PC GGT1 HPRT1 INS
2 homeostasis/metabolism MP:0005376 10.13 ABCG2 ADRB3 APOB CRP G6PC GGT1
3 growth/size/body region MP:0005378 10.1 ADRB3 APOB G6PC GGT1 HPRT1 INS
4 immune system MP:0005387 9.93 ABCG2 APOB CRP GGT1 HPRT1 INS
5 liver/biliary system MP:0005370 9.5 ABCG2 APOB G6PC HPRT1 INS SLC2A9
6 renal/urinary system MP:0005367 9.36 ABCG2 G6PC GGT1 HPRT1 INS REN

Drugs & Therapeutics for Hyperuricemia

Drugs for Hyperuricemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 193)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
2
Rasburicase Approved, Investigational Phase 4 134774-45-1
3
Colchicine Approved Phase 4 64-86-8 2833 6167
4
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
5
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
6
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
7
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
8
Polyestradiol phosphate Approved Phase 4 28014-46-2
9
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
10
Lithium carbonate Approved Phase 4 554-13-2
11
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
12
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
13
Angiotensin II Approved, Investigational Phase 4 4474-91-3, 11128-99-7, 68521-88-0 172198
14
Rutin Approved, Experimental, Investigational Phase 4 153-18-4 5280805
15
Canagliflozin Approved Phase 4 842133-18-0
16
Allopurinol Approved Phase 4 315-30-0 2094
17
Febuxostat Approved Phase 4 144060-53-7 134018
18
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
19
Rosemary Experimental Phase 4
20
Quercetin Experimental, Investigational Phase 4 117-39-5 5280343
21
Uric acid Investigational Phase 4 69-93-2 1175
22 Proanthocyanidin Phase 4
23 Calciferol Phase 4
24 Tubulin Modulators Phase 4
25 Antimitotic Agents Phase 4
26 Insulin, Globin Zinc Phase 4
27 insulin Phase 4
28 Antihypertensive Agents Phase 4
29 Angiotensin-Converting Enzyme Inhibitors Phase 4
30 Sodium Chloride Symporter Inhibitors Phase 4
31 diuretics Phase 4
32 Diacetylrhein Phase 4
33 Progestins Phase 4
34 Estradiol 17 beta-cypionate Phase 4
35
protease inhibitors Phase 4
36 Estradiol 3-benzoate Phase 4
37 HIV Protease Inhibitors Phase 4
38 Estrogens Phase 4
39 Gastrointestinal Agents Phase 4
40 Antipsychotic Agents Phase 4
41 Antacids Phase 4
42 Anti-Ulcer Agents Phase 4
43 Proton Pump Inhibitors Phase 4
44 Angiotensinogen Phase 4
45 Giapreza Phase 4
46 Sodium-Glucose Transporter 2 Inhibitors Phase 4
47 Hypoglycemic Agents Phase 4
48 Antioxidants Phase 4
49 Protective Agents Phase 4
50 Antimetabolites Phase 4

Interventional clinical trials:

(show top 50) (show all 192)
# Name Status NCT ID Phase Drugs
1 Investigation of the Atherogenic Effects of Uric Acid-modified in Endothelial Dysfunction and the the Preventional Mechanism by Anthocyanidines Unknown status NCT02797028 Phase 4 Allopurinol
2 Effect of Multi-vitamins With Minerals on Uric Acid Metabolism in Subjects With Hyperuricemia: A Randomized, Double-blinded, Placebo-controlled Trail Unknown status NCT03218709 Phase 4
3 The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics Unknown status NCT02956278 Phase 4 Allopurinol
4 Study on the Effect of Hyperuricaemia on Chronic Renal Disease and Intervention Unknown status NCT03425708 Phase 4 20mg Febuxostat;40mg Febuxostat
5 Program of Rasburicase in the Treatment of Hyperuricemia in Children and Adolescent Patients With or at Risk of Tumor Lysis Syndrome. Completed NCT00302653 Phase 4 Rasburicase
6 Phase IV, Compassionate Use Program of Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome Completed NCT00563771 Phase 4 Rasburicase
7 Prednisone Versus Allopurinol for Symptomatic Heart Failure Patients With Hyperuricemia Completed NCT00919243 Phase 4 prednisone;allopurinol
8 Hyperuricemia and the Effects of the Uricosuric Agents Benzbromarone in Patients With Chronic Heart Failure Completed NCT00422318 Phase 4 Benzbromarone (drug)
9 A Multicenter Open Label Study of the Efficacy and Safety of Rasburicase in the Treatment of Prophylysis for Tumor Lysis Syndrome Completed NCT00651911 Phase 4 urate oxidase
10 Febuxostat (Zurig) Efficacy & Safety Trial in Comparison With Allopurinol in Hyperuricemic Subjects With or Without Gout Completed NCT02600780 Phase 4 Febuxostat;Allopurinol
11 Effects of Pharmacological Reversal of Hyperuricemia on Features of the Metabolic Syndrome Completed NCT01654276 Phase 4 Febuxostat
12 A Double-blind, Placebo-controlled, Cross-over Study of the Effects of Allopurinol on Oxidative Metabolism, Peripheral Blood Flow and Immune Function in Patients With Advanced Chronic Heart Failure (CHF). Completed NCT00997542 Phase 4 Allopurinol;Placebo
13 Long-term Allopurinol Safety Study Evaluating Outcomes in Gout Patients (LASSO) Completed NCT01391325 Phase 4 Allopurinol
14 Evaluation of Single Agent Rasburicase in Treatment/Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Adult and Pediatric Patients With Lymphoma/Leukemia/Solid Tumor Malignancies at Their First Relapse or Refractory Disease Completed NCT00230217 Phase 4 Rasburicase (SR29142)
15 Diacerein Combined With Febuxostat Relieves Symptoms of Gout by Suppressing IL-1βinflammation Completed NCT02060552 Phase 4 Diacerein;Colchicine;Febuxostat
16 Reversal of an Unfavorable Effect of Hydrochlorothiazide Compared to Angiotensin Converting Enzyme Inhibitor on Serum Uric Acid and Oxypurines Levels by Estrogen-progestin Therapy in Hypertensive Postmenopausal Women. Completed NCT03921736 Phase 4 Perindopril;Hydrochlorothiazide;Estracomb TTS
17 Weight Loss Improves Renal Hemodynamics in Patients With Metabolic Syndrome Completed NCT01356394 Phase 4
18 A Double-Blind, Placebo Controlled Augmentation Study With Allopurinol for Treatment Resistant Mania Completed NCT00643123 Phase 4 Allopurinol
19 The Effect of Intensive Urate Lowering Therapy (ULT) With Febuxostat in Comparison With Allopurinol on Cardiovascular Risk in Patients With Gout Using Surrogate Markers: a Randomized, Controlled Trial Completed NCT02500641 Phase 4 Febuxostat 80/120mg/day;Allopurinol 100 up to 600mg/day;Colchicine;Naproxen;Omeprazole
20 Febuxostat, Blood Pressure and the Intrarenal Renin-Angiotensin System (RAS) Completed NCT01328769 Phase 4 Febuxostat;Placebo
21 An Open-label, Single-arm, Multi-center Study to Evaluate the Efficacy and Safety of Rasburicase (Fasturtec) in the Prevention and Treatment of Hyperuricemia in Pediatric Patients With Non-Hodgkin¿s Lymphoma and Acute Leukemia Recruiting NCT04349306 Phase 4 RASBURICASE SR29142
22 Lowering-hyperuricemia Treatment on Cardiovascular Outcomes in Peritoneal Dialysis Patients: A Prospective, Multicenter, Double-Blinded, Randomized Controlled Trial Recruiting NCT03200210 Phase 4 Febuxostat;Placebo
23 The Cardiovascular Effects of Febuxostat and Benzbromarone on Left Ventricle Diastolic Dysfunction in Individuals With Metabolic Syndrome and Hyperuricemia - an Open-label Non-blinded Randomized-controlled Clinical Trial Recruiting NCT03534037 Phase 4 Febuxostat 40 mg;Benzbromarone 50mg
24 Evaluation of the Effects of a Supplement Composed by Quercetin, Rutin, Bromelain and L-carnosine in Patients With Hyperuricemia, a Randomized Clinical Trial Active, not recruiting NCT04161872 Phase 4 Uricemin;Placebo
25 Pharmacogenetics of Sodium-dependent Glucose Transporter-2 (SGLT2) Inhibitors Active, not recruiting NCT02462421 Phase 4 Canagliflozin
26 Department of Urology, Shanghai Xu-hui Central Hospital Enrolling by invitation NCT04398251 Phase 4 Febuxostat 40mg Tab
27 The Impact of Urate-lowering Therapy on Kidney Function in Patients With/Without Gout Enrolling by invitation NCT03336203 Phase 4 Febuxostat 80 MG Oral Tablet or Allopurinol 300 MG Oral Tablet
28 A Single-center, Prospective, Randomized, Double-blind, Controlled Trial for the Effect of Allopurinol Sustained-release Capsules on the Stability of Coronary Plaques in Patients With Acute Coronary Syndrome Not yet recruiting NCT03745729 Phase 4 allopurinol sustained-release capsules;placebo capsules
29 the Effect of Febuxostat on Coronary Plaque Volume in Patients With Chronic Stable Angina and Hyperuricemia Terminated NCT02279342 Phase 4 Febuxostat
30 Ketorolac for Analgesia followiNG Autologous Breast RecOnstructiOn Withdrawn NCT03007381 Phase 4 Ketorolac Tromethamine;Normal Saline
31 Long-term Prednisone Use in Patients With Advanced Heart Failure (ACCF/AHA Stage D) and Hyperuricemia Unknown status NCT02282683 Phase 2, Phase 3 prednisone
32 The Effects of Doxazosin and Nifedipine on Blood Pressure Variability and Uric Acid in Plasma in Hypertensive Patients Unknown status NCT02563405 Phase 2, Phase 3 Doxazosin;Nifedipine
33 Official Title: Safety and Efficacy Evaluation Study of FYU-981 Long-term Administration for Hyperuricemia With or Without Gout (Phase III Study) Completed NCT03006445 Phase 3 FYU-981
34 Benzbromarone-Controlled, Double-Blind, Comparative Study of FYU-981 for Hyperuricemia With or Without Gout to Evaluate the Safety and Noninferiority of FYU-981 (Phase III Study) Completed NCT03100318 Phase 3 FYU-981;Benzbromarone
35 Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 for Hyperuricemia With or Without Gout to Evaluate the Safety and Noninferiority of FYU-981 (Phase III Study) Completed NCT03372200 Phase 3 FYU-981;Febuxostat
36 Prednisone in Uric Acid Lowering in Symptomatic Heart Failure PATients With Hyperuricemia (PUSH-PATH Study 2) Completed NCT02129764 Phase 2, Phase 3 Prednisone;Allopurinol
37 Evaluation of Single Agent Rasburicase for 5 Days Versus Sequential Treatment With Rasburicase From Day 1 Through 3 Followed by Oral Allopurinol From Day 3 Through 5 (Overlap on Day 3) Versus Single Agent Oral Allopurinol for 5 Days in the Management of Plasma Uric Acid in Adult Patients With Leukemia, Lymphoma, and Solid Tumor Malignancies at Risk for Hyperuricemia and Tumor Lysis Syndrome Completed NCT00230178 Phase 3 Rasburicase (SR29142);Allopurinol
38 Randomised Phase III Trial of Effectivity and Safety of Rasburicase Compared With Allopurinol for Treatment of Hyperuricemia in Patients With Acute Lymphoblastic Leukemia or High-Grade NHL With High Risk of Tumorlysis Syndrome (> 15 Yrs) Completed NCT00199043 Phase 3 Allopurinol;Rasburicase
39 A Phase 3, Randomized, Multicenter, Double-Blind, Allopurinol-Controlled Study Assessing the Efficacy and Safety of Oral Febuxostat in Subjects With Gout. Completed NCT00430248 Phase 3 Febuxostat;Febuxostat;Allopurinol
40 Efficacy and Safety of TULY in Prevention and Treatment of Malignancy-associated Hyperuricemia Completed NCT00921375 Phase 3 TULY
41 A Phase 3, Open-Label, Randomized, Allopurinol-Controlled Study to Assess the Long-Term Safety of Oral Febuxostat in Subjects With Gout Completed NCT00175019 Phase 3 Febuxostat;Febuxostat;Allopurinol
42 University of Alabama at Birmingham CORT Project 2: The Effects of Urate Lowing Therapy (ULT) in Inflammation, Endothelial Function, and Blood Pressure Completed NCT02038179 Phase 2, Phase 3 Allopurinol;Placebo
43 Uric Acid and Hypertension in African Americans Completed NCT00241839 Phase 3 Allopurinol;Placebo;Chlorthalidone;Potassium chloride
44 A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities Completed NCT01101035 Phase 3 Febuxostat;Allopurinol
45 Randomized, Multicenter, Double-blind, Placebo-controlled Efficacy and Safety Study of 8 mg PEG-uricase in Two Dose Regimens in Hyperuricemic Subjects With Symptomatic Gout Completed NCT00325195 Phase 3
46 Low Osmolar Diet and Adjusted Water Intake for Vasopressin Suppression in ADPKD Completed NCT02225860 Phase 2, Phase 3
47 BOsentan for Mild Pulmonary Vascular Disease in Asd Patients (the BOMPA Trial): a Double-blind, Randomized Controlled, Pilot Trial Completed NCT01218607 Phase 3 Bosentan;Placebo
48 Effects of Allopurinol on Inflammatory Markers and Morphostructural Changes Evidenced by Musculoskeletal Ultrasound in Individuals With Asymptomatic Hyperuricemia. A Proof of Concept Recruiting NCT04012294 Phase 3 Allopurinol Pill
49 Colchicine or Prednisone for the Treatment of Acute Calcium Pyrophosphate Deposition (CPPD) Arthritis: Open-label, Randomized, Multicenter, Equivalence Trial of Efficacy and Safety Recruiting NCT03128905 Phase 3 Colchicine opocalcium 1mg;Prednisone : Cortancyl 20mg
50 A Single-center, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Allopurinol in Improving Ischemic Symptoms in Patients With Refractory Angina. Enrolling by invitation NCT04368819 Phase 2, Phase 3 Allopurinol 300 MG;Placebo oral tablet

Search NIH Clinical Center for Hyperuricemia

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Mannitol hexanitrate
Rasburicase

Cochrane evidence based reviews: hyperuricemia

Genetic Tests for Hyperuricemia

Anatomical Context for Hyperuricemia

MalaCards organs/tissues related to Hyperuricemia:

40
Kidney, Heart, Liver, Endothelial, Bone, Testes, Breast

Publications for Hyperuricemia

Articles related to Hyperuricemia:

(show top 50) (show all 6808)
# Title Authors PMID Year
1
Childhood course of renal insufficiency in a family with a uromodulin gene mutation. 61 54
20151160 2010
2
Uric acid transport and disease. 61 54
20516647 2010
3
Glomerulocystic kidney: one hundred-year perspective. 61 54
20367310 2010
4
Uric acid as a factor in the metabolic syndrome. 61 54
20424936 2010
5
[Association between the risk factors of cardiovascular diseases and insulin resistance]. 61 54
20513276 2010
6
Trp64Arg polymorphism of the ADRB3 gene predicts hyperuricemia risk in a population from southern Spain. 61 54
20008926 2010
7
Allopurinol, xanthine oxidase, and cardiac ischemia. 54 61
19794315 2009
8
Serum uric acid is associated with metabolic risk factors for cardiovascular disease in the Uygur population. 54 61
20029511 2009
9
Uric acid concentrations are associated with insulin resistance and birthweight in normotensive pregnant women. 54 61
19729142 2009
10
Myelination disturbance in a patient with hyperuricemia and hyperserotoninemia combined with 18q deletion syndrome. 61 54
20025132 2009
11
Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout. 54 61
20109996 2009
12
Utility of waist-to-height ratio in detecting central obesity and related adverse cardiovascular risk profile among normal weight younger adults (from the Bogalusa Heart Study). 61 54
19699351 2009
13
Severe gouty arthritis and mild neurologic symptoms due to F199C, a newly identified variant of the hypoxanthine guanine phosphoribosyltransferase. 54 61
19565499 2009
14
Increased xanthine oxidase in the skin of preeclamptic women. 61 54
19196876 2009
15
Febuxostat (Uloric) for chronic treatment of gout. 54 61
19448587 2009
16
Hypertension in the metabolic syndrome: summary of the new position statement of the European Society of Hypertension. 61 54
19413186 2009
17
Relationship of serum gamma-glutamyltransferase to atherogenic dyslipidemia and glycemic control in type 2 diabetes. 61 54
19057528 2009
18
Hyperinsulinemia and insulin resistance are independently associated with plasma lipids, uric acid and blood pressure in non-diabetic subjects. The GISIR database. 54 61
18060751 2008
19
The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. 61 54
18635756 2008
20
[Uricosuric agent]. 61 54
18409525 2008
21
[Inhibitors of xanthine oxidoreductase]. 61 54
18409526 2008
22
[Primary hyperuricemia due to decreased renal uric acid excretion]. 61 54
18409514 2008
23
[Relationship between hyperuricemia and metabolic syndrome]. 61 54
18409529 2008
24
[Uromodulin mutation and hyperuricemia]. 61 54
18409531 2008
25
[New antihyperuricemic medicine: febuxostat, Puricase, etc]. 61 54
18409528 2008
26
Control of renal uric acid excretion and gout. 54 61
18349750 2008
27
In addition to insulin resistance and obesity, hyperuricemia is strongly associated with metabolic syndrome using different definitions in Chinese populations: a population-based study (Taichung Community Health Study). 54 61
18292110 2008
28
Substrate orientation in xanthine oxidase: crystal structure of enzyme in reaction with 2-hydroxy-6-methylpurine. 61 54
18063585 2008
29
Uric acid: a surrogate of insulin resistance in older women. 61 54
18082342 2008
30
Hypoxanthine-guanine phosophoribosyltransferase (HPRT) deficiency: Lesch-Nyhan syndrome. 54 61
18067674 2007
31
Diabetes and nephrolithiasis. 61 54
18255008 2007
32
Thiazide diuretics exacerbate fructose-induced metabolic syndrome. 54 61
17855639 2007
33
[Relation of serum uric acid levels with basic metabolic parameters in patients with metabolic syndrome during insulin-sensitizing therapy]. 61 54
18071212 2007
34
The metabolic syndrome in hypertension: diagnostic and therapeutic implications. 54 61
17686382 2007
35
The association between hyperuricemia and the Trp64Arg polymorphism of the beta-3 adrenergic receptor. 54 61
17225053 2007
36
Serum uric acid and leptin levels in metabolic syndrome: a quandary over the role of uric acid. 61 54
17512306 2007
37
Association between silent ST segment depression in exercise electrocardiography and insulin resistance in obese subjects. 61 54
17552288 2007
38
Prevalence of the metabolic syndrome in individuals with hyperuricemia. 61 54
17466656 2007
39
Elevated uric acid levels predict allograft vasculopathy in cardiac transplant recipients. 61 54
17449420 2007
40
Genetics and experimental models of crystal-induced arthritis. Lessons learned from mice and men: is it crystal clear? 54 61
17278928 2007
41
Febuxostat: a novel non-purine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in gout. 61 54
19075968 2007
42
Hypoxanthine-guanine phosphoribosyltransferase deficiency: biochemical and molecular findings in six Argentine patients. 61 54
17454734 2007
43
Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout. 54 61
17132810 2006
44
Association between intronic SNP in urate-anion exchanger gene, SLC22A12, and serum uric acid levels in Japanese. 61 54
16920156 2006
45
New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer). 61 54
17119268 2006
46
[An analysis of islet beta-cell function in hyperuricemia]. 54 61
16831320 2006
47
Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia. 61 54
16708061 2006
48
New developments in clinically relevant mechanisms and treatment of hyperuricemia. 54 61
16901081 2006
49
Metabolic syndrome in subjects with essential hypertension: relationships with subclinical cardiovascular and renal damage. 61 54
16778751 2006
50
Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. 54 61
16507884 2006

Variations for Hyperuricemia

Expression for Hyperuricemia

Search GEO for disease gene expression data for Hyperuricemia.

Pathways for Hyperuricemia

GO Terms for Hyperuricemia

Cellular components related to Hyperuricemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.76 XDH UMOD REN INS GPT GGT1
2 endosome lumen GO:0031904 9.26 INS APOB
3 apical plasma membrane GO:0016324 9.17 UMOD SLC2A9 SLC22A12 SLC17A3 SLC17A1 PFKM
4 brush border membrane GO:0031526 9.13 SLC22A12 SLC17A3 ABCG2

Biological processes related to Hyperuricemia according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 transmembrane transport GO:0055085 9.8 SLC37A4 SLC2A9 SLC22A12 SLC17A3 SLC17A1 ABCG2
2 cholesterol homeostasis GO:0042632 9.65 SLC37A4 G6PC APOB
3 glucose homeostasis GO:0042593 9.56 SLC37A4 PFKM INS G6PC
4 phosphate ion transmembrane transport GO:0035435 9.51 SLC37A4 SLC17A1
5 glycogen catabolic process GO:0005980 9.49 PFKM G6PC
6 response to carbohydrate GO:0009743 9.46 G6PC APOB
7 phosphate ion transport GO:0006817 9.43 SLC17A3 SLC17A1
8 negative regulation of blood vessel diameter GO:0097756 9.4 INS CRP
9 sialic acid transport GO:0015739 9.37 SLC17A3 SLC17A1
10 urate transport GO:0015747 9.35 SLC2A9 SLC22A12 SLC17A3 SLC17A1 ABCG2
11 glucose-6-phosphate transport GO:0015760 9.33 SLC37A4 SLC17A3 G6PC
12 urate metabolic process GO:0046415 9.1 SLC2A9 SLC22A12 SLC17A3 SLC17A1 G6PC ABCG2

Molecular functions related to Hyperuricemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 insulin-like growth factor receptor binding GO:0005159 9.4 REN INS
2 xenobiotic transmembrane transporter activity GO:0042910 9.37 SLC17A3 ABCG2
3 transmembrane transporter activity GO:0022857 9.35 SLC37A4 SLC2A9 SLC22A12 SLC17A3 SLC17A1
4 efflux transmembrane transporter activity GO:0015562 9.32 SLC17A3 ABCG2
5 sodium:phosphate symporter activity GO:0005436 9.26 SLC17A3 SLC17A1
6 sialic acid transmembrane transporter activity GO:0015136 9.16 SLC17A3 SLC17A1
7 urate transmembrane transporter activity GO:0015143 8.92 SLC2A9 SLC22A12 SLC17A3 ABCG2

Sources for Hyperuricemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....